Insured persons of the participating health insurance funds from the age of 18 who take five or more prescribed drugs and are initially hospitalised by the participating hospitals in an internal medicine ward, geriatrics, visceral surgery, vascular surgery, cardiac and thoracic surgery, orthopaedics as well as trauma surgery, neurology and urology during the study period.
Conditions
Interventions
Group 1: Treatment as usual
Group 2: Digitally supported medication therapy management process: Insured patients of the participating health insurance companies with polypharmacy are informed about th
Sponsors
Bergische Universität Wuppertal
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: All insured persons of the participating health insurance companies from the age of 18 who take five or more prescribed drugs and are initially admitted to an internal medicine ward, geriatrics, visceral surgery, vascular surgery, cardiac and thoracic surgery, orthopaedics as well as trauma surgery, neurology and urology by the participating hospitals during the study period are included. Inclusion in the study is consecutive. The study patients will be treated according to the group status of the respective hospital.
Exclusion criteria
Exclusion criteria: Patients undergoing oncological treatment are excluded, as they are regularly hospitalised due to treatment cycles.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The combined primary endpoint is whether TOP leads to a reduction in the mortality of hospitalised patients with polypharmacy (in hospital and up to 3 months after discharge) and/or the re-hospitalisation rate (within 3 months after discharge). | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients receiving inappropriate prescriptions; Proportion of patients experiencing serious preventable adverse drug reactions in hospital or within 3 months of discharge; Use of emergency outpatient care; Health-related quality of life; Patient empowerment; Experienced continuity of (pharmaceutical) care; Patient satisfaction with medication information received; Adherence; Self-reported adverse drug events; Perceived patient safety. Health economic aspect: Cost-effectiveness and cost-utility of the intervention compared to standard care; Costs and benefits (financial, resources/time, intangible) of the intervention at the level of stakeholders. | — |
Countries
Germany
Contacts
Public Contact; ;
AOK Nordost – Die Gesundheitskasse;BARMER
Outcome results
None listed